DORZOLAMIDE

Dorzolamide Hydrochloride [Cas No. 130693-82-2] is a carbonic anhydrase inhibitor API widely used for treatment of glaucoma and ocular hypertension. Dorzolamide Hydrochloride inhibits carbonic anhydrase in the ciliary body by which it reduces aqueous humor production and lowers intraocular pressure [IOP]. When IOP is reduced, optic nerve is protected, and vision is preserved making Dorzolamide Hydrochloride a key component in both monotherapy and fixed dose combination treatment. Dorzolamide is administered topically and has good safety profile with targeted ocular action and systemic absorption is very low which makes it first choice for glaucoma therapy.

Chemox Pharma is a leading manufacturer and supplier of Dorzolamide Hydrochloride which meets global regulatory standards and quality specifications. Chemox Pharma also house a well-equipped R&D Centre, focused on process development, quality improvement, and cost optimization—empowering us to meet the evolving needs of the global pharmaceutical industry.